[go: up one dir, main page]

PE20000547A1 - COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION - Google Patents

COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Info

Publication number
PE20000547A1
PE20000547A1 PE1999000419A PE00041999A PE20000547A1 PE 20000547 A1 PE20000547 A1 PE 20000547A1 PE 1999000419 A PE1999000419 A PE 1999000419A PE 00041999 A PE00041999 A PE 00041999A PE 20000547 A1 PE20000547 A1 PE 20000547A1
Authority
PE
Peru
Prior art keywords
phentholamine
treatment
sexual dysfunction
fentholamine
combination
Prior art date
Application number
PE1999000419A
Other languages
Spanish (es)
Inventor
Thomas Mark Estok
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20000547A1 publication Critical patent/PE20000547A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)MESILATO DE FENTOLAMINA; b)UN INHIBIDOR DE 3`,5'-MONOFOSFATO DE FOSFODIESTERASA GUANOSINA CICLICA TIPO V (PDE cGMPV), SIENDO DE PREFERENCIA CITRATO DE SILDENAFILO, (6R, 12aR)-2,3,6,7,12,12a-HEXAHIDRO-2-METIL-6-(3,4-METILENDIOXIFENIL)-PIRAZINO[2'1':6,1]PIRIDO[3,4-b]INDOL-1,4-DIONA, (3S,6R,12aR)-2,3,6,7,12,12a-HEXAHIDRO-2,3-DIMETIL-6-(3,4-METILENDIOXIFENIL)-PIRAZINO[2',1':6,1]PIRIDO[3,4-b]-INDOL-1,4-DIONA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN PRIMER Y UN SEGUNDO AGENTE VASODILATADOR; EL PRIMER AGENTE ES UN AGENTE DE BLOQUEO ALFA-1 ADRENERGICO O ALFA-2 ADRENERGICO TAL COMO FENTOLAMINA, MESILATO DE FENTOLAMINA, CLORHIDRATO DE FENTOLAMINA, FENOXIBENZAMINA, TOLAZOLINA, DIBENAMINA, YOHIMBINA, TERAZOSINA, DOXAZOSINA, PRAZOSINA. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISFUNCION SEXUALREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING a) PHENTHOLAMINE MESILATE; b) AN INHIBITOR OF 3`, 5'-CYCLIC GUANOSINE PHOSPHODIESTERASE MONOPHOSPHATE TYPE V (PDE cGMPV), OF PREFERENCE SILDENAPHYL CITRATE, (6R, 12aR) -2,3,6,7,12,12a-HEXAHYDRO- 2-METHYL-6- (3,4-METHYLENEDIOXIPHENYL) -PYRAZINE [2'1 ': 6.1] PYRID [3,4-b] INDOL-1,4-DIONA, (3S, 6R, 12aR) -2 , 3,6,7,12,12a-HEXAHYDRO-2,3-DIMETHYL-6- (3,4-METHYLEDIOXYPHENYL) -PYRAZINE [2 ', 1': 6.1] PYRID [3,4-b] - INDOL-1,4-DIONA. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES A FIRST AND A SECOND VASODILATING AGENT; THE FIRST AGENT IS AN ALPHA-1 ADRENERGIC OR ALPHA-2 ADRENERGIC BLOCKING AGENT SUCH AS PHENTHOLAMINE, PHENTHOLAMINE MESYLATE, PHENTHOLAMINE HYDROCHLORIDE, PENOXYBENZAMINE, TOLAZOLINE, DIBENAMINE, PTHAZHIMBINE, TERAZHIMBINE, TERAZHIMBINE. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF SEXUAL DYSFUNCTION

PE1999000419A 1998-05-20 1999-05-18 COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PE20000547A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8164098A 1998-05-20 1998-05-20
US8297798A 1998-05-21 1998-05-21
US10651798A 1998-06-29 1998-06-29

Publications (1)

Publication Number Publication Date
PE20000547A1 true PE20000547A1 (en) 2000-07-15

Family

ID=27374039

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000419A PE20000547A1 (en) 1998-05-20 1999-05-18 COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Country Status (3)

Country Link
AU (1) AU4068599A (en)
PE (1) PE20000547A1 (en)
WO (1) WO1999059584A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161255A4 (en) * 1999-03-08 2002-07-17 Merck & Co Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
BRPI0003386B8 (en) 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
JP2009513604A (en) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazolone derivatives for the treatment of premenstrual disorders and other female sexual disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
BRPI0716439B8 (en) 2006-08-14 2021-05-25 Boehringer Ingelheim Int pharmaceutical delivery systems comprising flibanserin, process for preparation and use thereof
BRPI0716436B8 (en) 2006-08-25 2021-05-25 Boehringer Ingelheim Int controlled release system and method for manufacturing it
PE20091188A1 (en) 2007-09-12 2009-08-31 Boehringer Ingelheim Int COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146249T3 (en) * 1993-02-10 2000-08-01 Bmra Corp Bv PHARMACEUTICAL COMPOSITION TO TREAT THE IMPOTENCE CONTAINED BY AN ALPHA-1 INHIBITOR AND AN ALPHA-2 INHIBITOR.
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments

Also Published As

Publication number Publication date
WO1999059584A1 (en) 1999-11-25
AU4068599A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
PE20000547A1 (en) COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
TR200200989T2 (en) Pharmaceutically active compounds.
MA29885B1 (en) 2-AMINO-7,8-DIHYDRO-6H-PYRIDO [4,3-D] PYRIMIDINE -5-ONES
NO20010743L (en) Antiviral indoloxoacetyl-piperazine derivatives
TR200003039T2 (en) Pirazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunctions
WO2006000922A3 (en) 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
AR022665A1 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
LU92323I2 (en) The combination of (a) dextromethorphan or a pharmaceutically acceptable salt thereof, precursors or derivatives, e.g. dextromethorphan hydrobromide and in particular dextromethorphan hydrobromide monohydrate; and (b) quinidine or a pharmaceutically acceptable salt thereof, precursors or derivatives, e.g. quinidine sulfate and in particular quinidine sulfate dihydrate
DK1646389T3 (en) Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY130681A (en) Compositions and methods for treating female sexual dysfunction
IN2012DN06436A (en)
TNSN05176A1 (en) DIAZEPINO-INDOLE DERIVATIVES AS INHIBITORS OF KINASES
MA30725B1 (en) ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS
PE20000702A1 (en) INTRANASAL FORMULATIONS TO TREAT SEXUAL DISORDERS
IL164491A0 (en) Non nucleoside reverse transcriptase inhibitors
PE20010924A1 (en) USEFUL PHOSPHODIESTERASE INHIBITING COMPOUNDS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
AR027464A1 (en) OXAMIDS THAT ARE INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH)
BRPI0412327A (en) pyrimidine-2,4-dione derivatives as gonadotropin releasing hormone receptor antagonists
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
WO2002000657A3 (en) Condensed pyrazindione derivatives
PT102457A (en) PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE INHIBITOR OF PDE5
PE20060594A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PPAR AGONIST
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
NO20002696L (en) New compounds with cGMP-PDE inhibitor effect
AR038858A1 (en) COMBINATION

Legal Events

Date Code Title Description
FA Abandonment or withdrawal